Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.34 |
| ▸ | DHPS | P49366 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956659 | 0.91 | LIPE (0.43) | LIPECXCR2DHPSMAPT | |
| SCHEMBL16343945 | 0.87 | LIPE (0.47) | LIPEDHPSKDM4EMAPTPPARG | |
| SCHEMBL3705786 | 0.85 | LIPE (0.42) | LIPE | |
| SCHEMBL3720444 | 0.85 | LIPE (0.46) | LIPECXCR2LMNAMAPT | |
| SCHEMBL15957110 | 0.84 | LIPE (0.45) | LIPECXCR2DHPSMAPTNR1H4 | |
| SCHEMBL15526258 | 0.81 | LIPE (0.45) | LIPECXCR2 | |
| SCHEMBL15956897 | 0.78 | LIPE (0.43) | LIPELMNA | |
| SCHEMBL15979558 | 0.77 | LIPE (0.47) | LIPEDHPSMAPTPPARGNR1H4 | |
| SCHEMBL18130771 | 0.77 | ALDH1A1 (0.42) | KDM4ELMNATSHRMAPT | |
| SCHEMBL3872643 | 0.77 | LIPE (0.42) | LIPECXCR2DHPSCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | LIPE 4032/4885CXCR2 413/4885DHPS 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.